MLMary S. Leffell

Mary S. Leffell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mary S. Leffell has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HLA Mismatching Strategies for Solid Organ Transplantation – A Balancing Act

    by Andrea A. Zachary, Mary S. Leffell

    HLA matching provides numerous benefits in organ transplantation including better graft function, fewer rejection episodes, longer graft survival, and the possibility of reduced immunosuppression. Mismatches are attended by more frequent rejection episodes that require increased immunosuppression that, in turn, can increase the risk of infection and malignancy. HLA mismatches also incur the risk of sensitization, which can reduce the opportunity and increase waiting time for a subsequent transplant. However, other factors such as donor age, donor type, and immunosuppression protocol, can affect the benefit derived from matching. Further, finding a well matched donor may not be possible for all patients and usually prolongs waiting time. Strategies to optimize transplantation for patients without a well matched donor should take into account the immunologic barrier represented by different mismatches: what are the least immunogenic mismatches considering the patient’s HLA phenotype; should repeated mismatches be avoided; is the patient sensitized to HLA and, if so, what are the strengths of the patient’s antibodies? This information can then be used to define the HLA type of an immunologically optimal donor and the probability of such a donor occurring. A probability that is considered to be too low, may require expanding the donor population through paired donation or modifying what is acceptable which may require employing treatment to overcome immunologic barriers such as increased immunosuppression or desensitization. Thus, transplantation must strike a balance between the risk associated with waiting for the optimal donor and the risk associated with a less than optimal donor.


  • Donor HLA-specific Abs: to BMT or not to BMT?

    by M S Leffell, R J Jones, D E Gladstone

    The engraftment failure associated with Abs to donor-specific HLA (DSA) limits options for sensitized BMT candidates. Fourteen of fifteen patients with no other viable donor options were desensitized and transplanted using a regimen of plasmapheresis and low-dose i.v. Ig modified to accommodate pre-BMT conditioning. DSA levels were assessed by solid-phase immunoassays and cell-based crossmatch tests. DSA levels were monitored throughout desensitization and on day −1 to determine if there was any DSA rebound that would require additional treatment. A mean reduction in DSA level of 64.4% was achieved at the end of desensitization, with a subsequent reduction of 85.5% after transplantation. DSA in 11 patients was reduced to levels considered negative post-BMT, whereas DSA in three patients remained at low levels. All 14 patients achieved donor engraftment by day +60; however, seven patients suffered disease relapses. Four patients experienced mild, grade 1 GVHD. Factors influencing the response to desensitization include initial DSA strength, number, specificity, DSA rebound and a mismatch repeated from a prior transplant. While desensitization should be reserved for patients with limited donor options, careful DSA assessment and monitoring can facilitate successful engraftment after BMT.


  • Two Year Impact of Calculated PRA (CPRA) on Increasing Transplantation of Sensitized Patients

    by N. L. Reinsmoen, L. A. Baxter-Lowe, J. M. Cecka, M. S. Leffell, L. A. Gore, A. Y. Kucheryavaya

  • The calculated panel reactive antibody policy

    by Mary S. Leffell

    A major policy change affecting renal organ allocation to sensitized patients in the US was implemented in October, 2009. Extra allocation points are awarded to sensitized patients based on a calculated panel reactive antibody (CPRA). This review will discuss the reasons underlying this policy change and examine the evidence to date of its impact on renal allocation. Comparison of both the proportion and transplant rates of sensitized renal transplant candidates during the 6 months prior to the policy implementation and 6 months after implementation showed a significant increase in transplantation of sensitized patients, with the greatest difference occurring among broadly sensitized patients with CPRA values of 80 or greater. Whereas there was a decrease in transplant rates among candidates with CPRA values from 1 to 20, both this decrease and the increased rates among the more highly sensitized recipients were proportional to the distributions of these groups on the wait list. Notably, following the policy change, there was a highly significant decrease in organ refusals due to positive cross-matches with an 83% reduction between the 6-month periods prior to and after the policy implementation. Additional analyses have recently shown the continuation of these trends 1 year after the policy implementation. Implementation of the CPRA policy on national renal organ allocation in the US has increased efficiency in organ allocation and is helping to facilitate transplantation of broadly sensitized candidates.


  • Antiallograft antibodies: relevance, detection, and monitoring

    by Mary S Leffell, Andrea A Zachary

    Solid-phase immunoassays increase the accuracy of assessing pretransplant immunologic risk and facilitate posttransplant prediction and diagnosis of antibody-mediated rejection (AMR). This review will describe methods available for antibody analyses, discuss the types of targets of AMR and the characteristics of pathogenic alloantibodies, and provide guidelines for the application of antibody tests in the prediction of rejection risk and diagnosis of rejection. The presence of human leukocyte antigen-specific antibodies increases the risk of AMR, but the clinical relevance of low antibody levels is questioned with reports of stable graft function in their presence. Posttransplant monitoring has been shown to provide early diagnosis of AMR permitting preemptive intervention. Antibodies to other alloantigens and autoantigens are being implicated as potential targets for both acute and chronic AMR. Certain limitations and interfering factors have also been recognized that should be recognized in the interpretation of solid-phase antibody assay results. Contemporary technology is clearly advancing the detection of various antibodies that can contribute to AMR, but continued work is needed to elucidate the relevance of very low levels of human leukocyte antigen-specific antibody and the importance of antibodies to other alloantigens and autoantigens.


  • Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation

    by M. S. Leffell, K. Cao, M. Coppage, J. A. Hansen, J. M. Hart, N. Pereira, S. Pereira, N. L. Reinsmoen, D. Senitzer, A. Smith, et al.

    As part of the 15th International Histocompatibility and Immunogenetics Workshop (IHIWS), seven centers participated in a collaborative project to determine whether any significant humoral sensitization occurred post‐transplant among recipients of HLA partially mismatched hematopoietic cell transplants (HCTs). A total of 140 donor/recipient pairs were enrolled with a total of 367 pre‐and post‐transplant sera analyzed. The majority of the samples (69.1%) were obtained within 30–90 days post‐HCT. HLA‐specific antibodies were defined using single antigen bead assays on a Luminex™ platform with a positive cutoff value of 1000 normalized median fluorescence intensity (MFI). There was an overall incidence of post‐HCT sensitization toward donor HLA mismatches of 5.7%; however, all cases were among recipients of one HLA haplotype‐mismatched grafts under nonmyeloablative, pre‐transplant conditioning. Among the one haplotype‐mismatched recipients, 15.7% (8/51) developed donor HLA‐specific antibodies and 29.4% also had antibodies directed toward third party HLA antigens. Among the donor‐specific antibodies, 9.8% were directed toward HLA class I antigens; 7.8% were against class II antigens; and 2.0% had both class I and II specificity. The relative strength of post‐transplant antibodies was low with no significant difference in the mean maximum MFI values between third party and donor‐specific antibodies. Because only a small number (10.2%) of the post‐transplant samples were obtained 180 days or more post‐HCT, longer term study is needed to evaluate any clinical relevance of these low‐to‐moderate levels of donor‐specific antibody in one haplotype‐mismatched recipients, as well as to determine whether any other antibodies occur at later times.


  • The role of the histocompatibility laboratory in desensitization for transplantation

    by Mary S Leffell, Andrea A Zachary

    The ability of histocompatibility laboratories to define and monitor human leukocyte antigen (HLA)-specific antibodies via highly sensitive immunoassays has been a major contributing factor in the development of desensitization protocols for HLA-incompatible transplants. This review will focus on the laboratory's role in desensitization and the types of tests needed for determining the specificity and strength of antibodies to donor HLA pretransplant, during treatment, and after transplant. Increasingly, solid-phase immunoassays that use purified HLA molecules are providing sensitive characterization of HLA-specific antibodies. Assay parameters, such as median fluorescence intensity, can be correlated with cross-match results and clinical outcomes, and subsequently used to monitor antibody status in patients undergoing desensitization. The strength of donor HLA-specific antibody, measured by cross-match and/or solid phase assays, is used to determine the likelihood of successful desensitization, as well as the risk of posttransplant antibody-mediated rejection. Histocompatibility laboratories are essential components of desensitization programs. Thorough antibody characterization and serial monitoring of changes in antibody status are needed pretreatment, during treatment and after transplant. Because clinical decisions rely heavily on changes in antibody specificity and strength, desensitization should not be undertaken without access to appropriate histocompatibility testing.


  • The effect of the kidney-pancreas exemption on waiting time and match

    by J.M. Hart, G.L. Lay, A.A. Zachary, M.S. Leffell

  • Cadaver donor age and organ wastage

    by K.A. Hopkins, W.B. Bias, J.M. Hart, M.S. Leffell